申请人:Bongartz Jean-Pierre Andre Marc
公开号:US20100210618A1
公开(公告)日:2010-08-19
The invention relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —O—C(═O)—; —C(═O)—C(═O)—; —NR
X
—C(═O)—; —Z—C(═O)—; —Z—NR
X
—C(═O)—; —C(═O)—Z—; —NR
X
—C(═O)—Z—; —C(═S)—; —NR
X
—C(═S)—; —Z—C(═S)—; —Z—NR
X
—C(═S)—; —C(═S)—Z—; —NR
X
—C(═S)—Z—; Z represents a bivalent radical selected from C
1-6
alkanediyl, C
2-6
alkenediyl or C
2-6
alkynediyl; wherein each of said C
1-6
alkanediyl, C
2-6
alkenediyl or C
2-6
alkynediyl may optionally be substituted; and wherein two hydrogen atoms attached to the same carbon atom in C
1-6
alkanediyl may optionally be replaced by C
1-6
alkanediyl; Y represents —C(═O)—NR
X
— or —NR
X
—C(═O)—; R
1
represents adamantanyl, C
3-6
cycloalkyl; aryl
1
or Het
1
; R
2
represents C
3-6
cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C
3-6
Cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl or heterocycle may optionally be substituted; R
7
represents hydrogen, halo, C
1-4
alkyl, C
1-4
alkyl substituted with hydroxyl; provided that the following compounds (II), (III) are excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine, as a DGAT inhibitor, of said compounds.